The daily business briefing: October 23, 2020
New jobless claims fell below 800,000 last week, the FDA approves remdesivir for COVID-19 treatment, and more


A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
1. Weekly new jobless claims fall below 800,000
The number of Americans filing new jobless claims has declined to less than 800,000 for the first time in seven months. The Labor Department on Thursday said that 787,000 Americans filed new jobless claims last week, a decline of 55,000 from the previous week's revised level and significantly below the expected 875,000 claims. It was the first time since the middle of March that the number of claims was below 800,000. Additionally, the number of continuing claims declined by about 1 million to 8.37 million claims. Last week, the number of new jobless claims unexpectedly rose to the highest level in almost two months. At the same time, CNN notes that "23.2 million Americans received some form of government jobless benefits in the week ended October 3."
2. FDA approves remdesivir for COVID-19 treatment
The Food and Drug Administration on Thursday approved remdesivir to treat COVID-19, making Gilead Science's antiviral drug the first and only coronavirus treatment with full federal approval. The FDA gave remdesivir emergency-use authorization in May, giving doctors the option of administering the drug to hospitalized COVID-19 patients after an extensive consent process. Full approval required further evidence of the drug's safety and effectiveness, which came through three clinical trials. A National Institutes of Health-funded trial found that remdesivir reduced hospital stays for moderately ill patients by four days, from 15 to 11. The drug has not been shown to significantly reduce mortality, and a multi-country trial backed by the World Health Organization found the drug had "little to no effect."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. Walmart files pre-emptive opioid lawsuit against federal government
Walmart on Thursday filed a pre-emptive lawsuit ahead of a looming Justice Department civil suit against the retailer in connection with the opioid crisis. Walmart accused DOJ and the Drug Enforcement Administration of trying to scapegoat the giant retail chain to hide their own "profound" regulatory and enforcement failings in the fight against the deadly opioid epidemic. Walmart said federal authorities were trying to impose harsh financial penalties by arguing that Walmart's pharmacists have filled dubious prescriptions for addictive painkillers. Walmart's suit argues that the federal government has no legal basis for suing Walmart, which operates more than 5,000 in-store pharmacies in the United States. The Justice Department and DEA declined to make any immediate comment.
4. Mortgage rates fall to 11th low of 2020
Mortgage rates fell to their 11th record low of the year last week. The average rate on a 30-year fixed-rate mortgage dropped to 2.8 percent, the lowest level in nearly 50 years, according to Freddie Mac. The 15-year fixed-rate mortgage fell to 2.33 percent. Today's rates are more than a full percentage point lower than they have been over the last five years, said Sam Khater, Freddie Mac's chief economist. "This means that most low- and moderate-income borrowers who purchased during the past few years stand to benefit by exploring refinancing to lower their monthly payment," Khater said. Unfortunately for buyers, prices are rising as the number of available homes declines. The median home price jumped by 15 percent in September over the same month last year.
5. Stocks rise slightly as coronavirus stimulus talks remain in focus
U.S. stock index futures edged higher early Friday as investors continued to monitor talks on a new round of coronavirus relief. Futures for the Dow Jones Industrial Average were up by 0.3 percent several hours before the opening bell. Those of the S&P 500 rose by 0.2 percent, while those of the tech-heavy Nasdaq were up by less than 0.1 percent. The Dow and the S&P 500 gained 0.5 percent on Thursday. The Nasdaq closed up by 0.2 percent. Investors also were monitoring earnings. Intel shares dropped by 9 percent after the chip maker reported mixed quarterly results. Coronavirus developments also remained in focus after the Food and Drug Administration made Gilead Sciences' drug remdesivir the first drug to receive full federal approval for treating COVID-19 patients.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Harold Maass is a contributing editor at TheWeek.com. He has been writing for The Week since the 2001 launch of the U.S. print edition. Harold has worked for a variety of news outlets, including The Miami Herald, Fox News, and ABC News. For several years, he wrote a daily round-up of financial news for The Week and Yahoo Finance. He lives in North Carolina with his wife and two sons.
-
'Poisonous'
Today's Newspapers A round-up of the headlines from the UK front pages
By The Week Staff Published
-
Drug could allow you to 'grow new teeth'
Tall Tales And other stories from the stranger side of life
By Chas Newkey-Burden Published
-
Ten Things You Need to Know Today: 27 September 2023
The Week’s daily digest of the news agenda, published at 8am
By The Week Staff Published
-
The daily business briefing: September 26, 2023
Business Briefing Ford halts work at $3.5 billion electric-vehicle battery plant, Costco offers members basic health care services, and more
By Harold Maass Published
-
The daily business briefing: September 25, 2023
Business Briefing Hollywood writers reach deal that would end strike, Canadian autoworkers ratify a new contract with Ford, and more
By Harold Maass Published
-
China: a superpower’s slump
The Explainer After 40 years of explosive growth, China’s economy is now in deep distress — with no turnaround in sight
By The Week Staff Published
-
The daily business briefing: September 22, 2023
Business Briefing Rupert Murdoch steps down as Fox, News Corp. chair, Cisco to buy Splunk in $28 billion cash deal, and more
By Harold Maass Published
-
The daily business briefing: September 21, 2023
Business Briefing The Fed leaves rates unchanged, Biden cancels debts for University of Phoenix borrowers, and more
By Harold Maass Published
-
The daily business briefing: September 20, 2023
Business Briefing Disney says it will invest $60 billion in theme parks, Instacart shares rise in debut, and more
By Harold Maass Published
-
The daily business briefing: September 19, 2023
Business Briefing Instacart prices its shares at top of range in IPO, the UAW threatens to widen its strike, and more
By Harold Maass Published
-
The daily business briefing: September 18, 2023
Business Briefing UAW strike continues after union rejects latest offer, China detains some Evergrande wealth management staff, and more
By Harold Maass Published